Hester Biosciences Profit Jumps 3-Fold in Q3 | Animal Healthcare
By Rediff Money Desk, New Delhi Jan 30, 2025 15:50
Hester Biosciences reported a significant profit increase in Q3 2024-25, driven by foreign exchange gains. Revenue dropped slightly, with animal healthcare declining, while poultry and pet care segments saw growth.
New Delhi, Jan 30 (PTI) Hester Biosciences Ltd on Thursday reported a nearly three-fold jump in profit for the December quarter of 2024-25, mainly driven by foreign exchange gains.
The company's profit after tax stood at Rs 11.41 crore in the October-December quarter of 2024-25 compared to Rs 4.02 crore in the year-ago period, an exchange filing said.
Revenue from operations dropped by 6 per cent to Rs 63.22 crore for the third quarter of 2024-25 compared to Rs 66.98 crore in the year-ago period. The company recorded an unrealised foreign exchange gain of Rs 7.83 crore due to currency fluctuations.
Revenue from animal healthcare division dropped 24 per cent while that from poultry segment rose by 12 per cent and from pet care more than doubled during the quarter.
Rajiv Gandhi, CEO and MD of Hester Biosciences said, Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is expected to significantly enhance the performance of the Poultry Healthcare Division and create new export opportunities.
Shares of Hester Biosciences, a leading animal vaccines and health products manufacturer, dropped 1.6 per cent to Rs 2,064 on BSE.
The company's profit after tax stood at Rs 11.41 crore in the October-December quarter of 2024-25 compared to Rs 4.02 crore in the year-ago period, an exchange filing said.
Revenue from operations dropped by 6 per cent to Rs 63.22 crore for the third quarter of 2024-25 compared to Rs 66.98 crore in the year-ago period. The company recorded an unrealised foreign exchange gain of Rs 7.83 crore due to currency fluctuations.
Revenue from animal healthcare division dropped 24 per cent while that from poultry segment rose by 12 per cent and from pet care more than doubled during the quarter.
Rajiv Gandhi, CEO and MD of Hester Biosciences said, Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is expected to significantly enhance the performance of the Poultry Healthcare Division and create new export opportunities.
Shares of Hester Biosciences, a leading animal vaccines and health products manufacturer, dropped 1.6 per cent to Rs 2,064 on BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.95 (+ 0.51)
- 12558479
- Sharanam Infra
- 0.90 (+ 4.65)
- 7775424
- Dolphin Offshore Ent
- 215.85 (+ 4.99)
- 4628666
- Spicejet Ltd.
- 44.75 ( -6.71)
- 4304721
- Thinkink Picturez
- 0.31 ( -3.13)
- 3550689
MORE NEWS

Godrej Properties Sells ₹1,000 Cr Pune Project
Godrej Properties has sold ₹1,000 crore worth of residential properties in its new...

Rupee Falls to 87.41 Against US Dollar
The Indian rupee weakened against the US dollar in early trade on Thursday, driven by...

Glenmark Launches Generic Epinephrine Injection...
Glenmark Pharmaceuticals launches generic Epinephrine injection in the US, eligible for...